(Q35174009)

6 August 2017

1 reference

title

Achieving low target pressures with today's glaucoma medications (English)

1 reference

6 August 2017

Louis Cantor

1

1 reference

6 August 2017

publication date

1 April 2003

1 reference

6 August 2017

published in

Survey of Ophthalmology

1 reference

6 August 2017

volume

48 Suppl 1

1 reference

6 August 2017

page(s)

S8-16

1 reference

The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Formulation effects on ocular absorption of brimonidine in rabbit eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Drug therapy: patient compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Patient compliance in glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Targeting outflow facility in glaucoma management

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Mechanism of action of bimatoprost (Lumigan).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Nephrolithiasis with dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Progress in the treatment of glaucoma in my lifetime

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Combination of systemic acetazolamide and topical dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Relationship between intraocular pressure and preservation of visual field in glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Treatment for glaucoma: adherence by the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Irreversible corneal decompensation in patients treated with topical dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Longterm timolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Compliance with treatment of patients with chronic open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Laboratory and clinical studies on the mechanism of action of timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

The lack of efficacy of topical beta-blockers, timolol and betaxolol on intraocular pressure in Nigerian healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Systemic adverse effects associated with topically applied latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Antiglaucoma medications: a review of safety and tolerability issues related to their use.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Target pressure--glaucomatologists' holey grail.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Ocular Beta-Blockers and Systemic Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2803%2900009-2

7 January 2021

10.1016/S0039-6257(03)00009-2

Identifiers

DOI

1 reference

6 August 2017

1 reference